Media stories about Oxford Immunotec Global (NASDAQ:OXFD) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Oxford Immunotec Global earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.0560831747343 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news stories that may have impacted Accern Sentiment’s scoring:
- Oxford Immunotec Global (OXFD) Rating Reiterated by Robert W. Baird (americanbankingnews.com)
- Vermillion (VRML) & Oxford Immunotec Global (OXFD) Head to Head Comparison (americanbankingnews.com)
- Oxford Immunotec Global (OXFD) Expected to Post Quarterly Sales of $21.69 Million (americanbankingnews.com)
- Zacks: Analysts Expect Oxford Immunotec Global (OXFD) Will Announce Earnings of -$0.38 Per Share (americanbankingnews.com)
OXFD traded up $0.35 during trading on Thursday, reaching $13.05. The company had a trading volume of 174,414 shares, compared to its average volume of 212,262. The stock has a market capitalization of $324.18, a P/E ratio of -9.46 and a beta of -0.32. Oxford Immunotec Global has a 12-month low of $10.00 and a 12-month high of $19.51. The company has a current ratio of 5.37, a quick ratio of 4.92 and a debt-to-equity ratio of 0.34.
Several equities analysts have recently issued reports on the stock. BTIG Research set a $21.00 price target on shares of Oxford Immunotec Global and gave the company a “buy” rating in a report on Monday, December 18th. BidaskClub upgraded shares of Oxford Immunotec Global from a “sell” rating to a “hold” rating in a research note on Friday, December 15th. Zacks Investment Research cut shares of Oxford Immunotec Global from a “buy” rating to a “hold” rating in a research note on Tuesday, March 13th. ValuEngine upgraded shares of Oxford Immunotec Global from a “strong sell” rating to a “sell” rating in a research report on Wednesday, March 7th. Finally, Cowen reiterated a “buy” rating and issued a $15.00 price target on shares of Oxford Immunotec Global in a research report on Monday, January 22nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. Oxford Immunotec Global has an average rating of “Buy” and a consensus target price of $17.80.
In other Oxford Immunotec Global news, Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $12.01, for a total transaction of $36,030.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 8.11% of the company’s stock.
WARNING: This article was first posted by BBNS and is owned by of BBNS. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://baseballnewssource.com/2018/04/05/oxford-immunotec-global-oxfd-receiving-somewhat-positive-press-coverage-analysis-shows/2028359.html.
About Oxford Immunotec Global
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.